newsfilter
← Latest News
GlobeNewswire·

Synlogic Provides Corporate Update and Outlook for 2023

Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 CAMBRIDGE, Mass., Jan.